诊断学理论与实践 ›› 2025, Vol. 24 ›› Issue (01): 95-99.doi: 10.16150/j.1671-2870.2025.01.014
收稿日期:
2024-08-14
接受日期:
2024-10-08
出版日期:
2025-02-25
发布日期:
2025-02-25
通讯作者:
刘静 E-mail:819481137@qq.com基金资助:
HUANG Yu1,2, CUI Yuliang2, LIU Jing2()
Received:
2024-08-14
Accepted:
2024-10-08
Published:
2025-02-25
Online:
2025-02-25
摘要:
本文报告1例B型胰岛素抵抗综合征(type B insulin resistance syndrome, TBIRS)合并混合性结缔组织病患者。该患者为54岁男性,患有混合性结缔组织病,表现为多尿、口干、多饮、体重持续减轻、高血糖、黑棘皮症,实验室检查提示胰岛素抵抗、高胰岛素血症,最终诊断为TBIRS,给予糖皮质激素、羟氯喹及胰岛素增敏剂治疗。2周后患者多尿、口干、多饮减轻,血糖平稳,1个月后,黑棘皮症减轻,体重稳定,血糖平稳。TBIRS属于自身免疫疾病,在临床上罕见,患者多为中年女性,大部分病例以高血糖、高胰岛素血症表现为主,低血糖少见,主要依据临床表现诊断,治疗方案需根据症状及伴发的自身免疫疾病综合考虑。临床上TBIRS多伴有系统性红斑狼疮,而本文报道病例为TBIRS伴混合性结缔组织病,较罕见。TBIRS患者预后差,死亡率高,早期诊断及治疗有助于改善其预后。本例患者首次应用新型胰岛素增敏剂西格列他钠控制血糖,具有良好降糖效果,且证实联合应用免疫抑制剂治疗有效,为临床上早期发现此类疾病及精准治疗提供重要指导价值。
中图分类号:
黄玉, 崔玉良, 刘静. B型胰岛素抵抗综合征合并混合性结缔组织病1例诊治报道并文献复习[J]. 诊断学理论与实践, 2025, 24(01): 95-99.
HUANG Yu, CUI Yuliang, LIU Jing. Diagnosis and treatment of type B insulin resistance syndrome complicated by mixed connective tissue disease: a case report and literature review[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(01): 95-99.
[1] | KAHN C R, FLIER J S, BAR R S,et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man[J]. N Engl J Med, 1976, 294(14):739-745. |
[2] | 龚梓晔, 张梅. B型胰岛素抵抗综合征的诊治进展[J]. 国际内分泌代谢杂志, 2022, 42(4)280-283. |
GONG Z Y, ZHANG M. Progress in the diagnosis and treatment of type B insulin resistance syndrome[J]. Int J Endocrinol Metab, 2022, 42(4)280-283. | |
[3] | KLUBO-GWIEZDZINSKA J, LANGE M, COCHRAN E,et al. Combined immunosuppressive therapy induces remission in patients with severe type b insulin resistance: A prospective cohort study[J]. Diabetes Care, 2018, 41(11):2353-2360. |
[4] |
MARTINS L M, FERNANDES V O, CARVALHO M M D,et al. Type B insulin resistance syndrome: a systematic review[J]. Arch Endocrinol Metab, 2020, 64(4):337-348.
doi: S2359-39972020005003201 pmid: 32813762 |
[5] |
赵琳琳, 王守俊. B型胰岛素抵抗的临床特点分析[J]. 中国全科医学, 2020, 23(11):1431-1435.
doi: 10.12114/j.issn.1007-9572.2019.00.485 |
ZHAO L L, WANG S J. The clinical characteristics of type b insulin resistance[J]. Chin Gen Pract, 2020, 23(11)1431-1435. | |
[6] | BHAT S Z,LIM S, SIDHAYE A,et al. Type B insulin resistance syndrome: A rare cause of hypoglycemia[J]. JCEM Case Rep, 2023, 1(5):luad104. |
[7] |
ZHAO L, LI W, LIU L,et al. Clinical features and outcome analysis of type b insulin resistance syndrome: A single-center study in China[J]. J Clin Endocrinol Metab, 2023, 109(1):e175-e181.
doi: 10.1210/clinem/dgad461 pmid: 37536271 |
[8] | JI L, SONG W, FANG H,et al. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)[J]. Sci Bull (Beijing), 2021, 66(15):1571-1580. |
[9] | JIA W, MA J, MIAO H,et al. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)[J]. Sci Bull (Beijing), 2021, 66(15):1581-1590. |
[10] | WANG Y, LI H, GAO H,et al. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2022, 183:109171. |
[11] | 段霖, 王志娟, 陈璐, 等. 西格列他钠联合德谷门冬双胰岛素治疗2型糖尿病的临床研究[J]. 糖尿病新世界, 2024, 27(7):21-24. |
DUAN L, WANG Z J, CHEN L,et al. Clinical study of sitaglitat sodium combined with degu asparton insulin in the treatment of type 2 diabetes mellitus[J]. Diabetes New World, 2024, 27(7):21-24. | |
[12] | ISERI K, IYODA M, SHIKIDA Y,et al. Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature[J]. Diabet Med, 2017, 34(12):1788-1791. |
[13] | ŁEBKOWSKA A, KRENTOWSKA A, ADAMSKA A,et al. Type B insulin resistance syndrome associated with connective tissue disease and psoriasis[J]. Endocrinol Diabetes Metab Case Rep, 2020, 2020:20-27. |
[14] | OGAWA W, ARAKI E, ISHIGAKI Y,et al. New classification and diagnostic criteria for insulin resistance syndrome[J]. Diabetol Int, 2022, 13(2):337-343. |
[15] | 杨国庆, 窦京涛, 吕朝晖, 等. B型胰岛素抵抗综合征三例临床分析并文献复习[J]. 中华内科杂志, 2016, 55(1):11-15. |
YANG G Q, DOU J T, LU Z H,et al. Type B insulin resistance syndrome: 3 cases report and literature review[J]. Chin J Int Med, 2016, 55(1)11-15. | |
[16] | SOLLIER M, VIGOUROUX C, DUCKETT K,et al. Type B insulin resistance syndrome: A case report[J]. Diabetes Metab, 2024, 50(5):101549. |
[1] | 倪衡如, 林琳, 彭魁, 郝明丽, 王天歌, 高金丽. 上海社区人群代谢健康型肥胖、胰岛素抵抗与糖尿病发病风险的相关性研究[J]. 诊断学理论与实践, 2017, 16(04): 419-424. |
[2] | 高婧, 周莉, 石娟, 洪洁, 陈慧, 陈晨,. 多囊卵巢综合征患者胰岛素抵抗的新指标评估研究[J]. 诊断学理论与实践, 2016, 15(04): 415-420. |
[3] | 陈淳, 王家莉, 季承博, 布阿提卡木, 彭亦雩, 傅毅,. 抵抗素与脑梗死及其危险因素的相关性研究[J]. 诊断学理论与实践, 2015, 14(03): 279-282. |
[4] | 宋科秀, 曲伸,. 非酒精性脂肪性肝病线粒体相关的分子通路[J]. 诊断学理论与实践, 2014, 13(02): 125-128. |
[5] | 程雯, 马志强, 张妍, 徐婷, 陈淑雯,. 2型糖尿病患者体脂分布与胰岛素抵抗的关系[J]. 诊断学理论与实践, 2011, 10(05): 479-481. |
[6] | 张豫文, 洪洁,. 炎症因子与胰岛素抵抗[J]. 诊断学理论与实践, 2010, 9(01): 90-94. |
[7] | 李焱,. 中枢胰岛素抵抗与阿尔茨海默病发病关系的认识[J]. 诊断学理论与实践, 2009, 8(03): 248-251. |
[8] | 祝之明,. 胰岛素抵抗综合征与代谢综合征的异同及临床意义[J]. 诊断学理论与实践, 2009, 8(03): 244-247. |
[9] | 贾伟平,. 胰岛素抵抗在2型糖尿病发病机制中的作用[J]. 诊断学理论与实践, 2009, 8(03): 233-236. |
[10] | 邹大进, 田建卿,. 胰岛素抵抗与心血管疾病的关系[J]. 诊断学理论与实践, 2009, 8(03): 252-255. |
[11] | 邹大进, 吴鸿,. 胰岛素抵抗与肥胖的关系认识[J]. 诊断学理论与实践, 2009, 8(03): 237-239. |
[12] | 曲伸, 刘蒙, 高鑫,. 胰岛素抵抗与非酒精性脂肪性肝病关系的认识[J]. 诊断学理论与实践, 2009, 8(03): 240-243. |
[13] | 周密, 周健, 陆俊茜, 唐峻岭, 包玉倩, 贾伟平,. 新诊断的2型糖尿病患者血糖水平与胰岛素分泌及胰岛素抵抗的关系[J]. 诊断学理论与实践, 2009, 8(03): 269-272. |
[14] | 曹怡, 邹大进,. 胃旁路术如何改善胰岛素抵抗的机制[J]. 诊断学理论与实践, 2009, 8(03): 343-344. |
[15] | 陈玲燕, 刘青, 曲伸,. 非酒精性脂肪性肝病与胰岛素抵抗及糖脂代谢关系的研究[J]. 诊断学理论与实践, 2009, 8(03): 260-263. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||